Supplemental Appendix 2: Significant Drug-Drug Interactions

* + Agents independently associated with EPS or OMD
    - Bupropion
    - Chlorpromazine
    - Meclizine
    - Meperidine
    - Methyldopa
    - Metoclopramide
    - Perphenazine
    - Prochlorperazine
    - Promethazine
  + Agents that could interact with DRBAs via CYP450 (moderate-strong inducers/inhibitors)
    - CYP450 1A2 inducers
      * Phenytoin
      * Rifampin
      * Ritonavir
      * Smoking
      * Teriflunomide
    - CYP450 1A2 inhibitors
      * Ciprofloxacin
      * Enoxacin
      * Ethinyl estradiol
      * Fluvoxamine
      * Methoxsalen
      * Mexiletine
      * Oral contraceptives
      * Zafirlukast
      * Zileuton
    - CYP450 2D6 inhibitors
      * Bupropion
      * Cimetidine
      * Cinacalcet
      * Darifenacin
      * Dronedarone
      * Duloxetine
      * Fluoxetine
      * Fluvoxamine
      * Mirabegron
      * Paroxetine
      * Quinidine
      * Sertraline
      * Terbinafine
    - CYP450 3A4 inducers
      * Carbamazepine
      * Enzalutamide
      * Mitotane
      * Phenytoin
      * Rifampin
      * St. John’s wort
    - CYP450 3A4 inhibitors
      * Aprepitant
      * Atazanavir
      * Boceprevir
      * Cimetidine
      * Ciprofloxacin
      * Clarithromycin
      * Clotrimazole
      * Cobicistat
      * Conivaptan
      * Crizotinib
      * Cyclosporine
      * Diltiazem
      * Dronedarone
      * Erythromycin
      * Fluconazole
      * Fluvoxamine
      * Fosemprenavir
      * Grapefruit
      * Holkira Pak
      * Indinavir
      * Imatinib
      * Itraconazole
      * Ketoconazole
      * Idelalisib
      * Nefazodone
      * Nelfinavir
      * Netupitant
      * Posaconazole
      * Ritonavir
      * Technivie
      * Telaprevir
      * Telithromycin
      * Tofisopam
      * Troleandomycin
      * Verapamil
      * Veikira Pak
      * Voriconazole
  + Agents that could ameliorate/mask EPS or OMD symptoms
    - Propranolol
    - Amantadine
    - Anticholinergics
      * Diphenhydramine
      * Benzotropine
      * Trihexyphenidyl
    - Benzodiazepines
      * Lorazapam
      * Alprazolam
      * Clonazepam
      * Diazepam
    - VMAT2 inhibitors
      * Valbenazine
      * Tetrabenazine
      * Deutetrabenazine

Legend: This list includes only agents that are classified as moderate or strong CYP450 inhibitors or inducers. Moderate is defined as ≥ 2 to < 5-fold increase in exposure, or 50% to 80% decrease in clearance of substrate. Strong is defined as ≥ 5-fold increase in exposure, or >80% decrease in clearance of substrate

Resources:

1. Cytochrome P450 Drug Interactions. PL Detail-Document #320506. May 2016. Copyright © 2016 by Therapeutic Research Center. Stockton, CA 95219.
2. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. U.S. Food and Drug Administration, Silver Spring, MD. Last updated: 11/14/2017. Accessed at: https://www.fda.gov/drugs/developmentapprovalprocess/development resources/druginteractionslabeling/ucm093664.htm